恒瑞医药(01276.HK)：SHR-1894注射液获批开展临床试验

Core Viewpoint - Heng Rui Medicine (01276.HK) announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials for SHR-1894 injection, a self-developed therapeutic biological product for atopic dermatitis treatment [1] Group 1 - SHR-1894 injection is expected to protect skin barriers and suppress inflammation during atopic dermatitis treatment [1] - As of now, there are no similar drugs approved for market release domestically or internationally [1] - The total research and development investment for SHR-1894 injection has reached approximately 40.1 million yuan (unaudited) [1]